Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CYCCP's Cash to Debt is ranked higher than
98% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. CYCCP: No Debt )
CYCCP' s 10-Year Cash to Debt Range
Min: 1.16   Max: No Debt
Current: No Debt

Interest Coverage No Debt
CYCCP's Interest Coverage is ranked higher than
92% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYCCP: No Debt )
CYCCP' s 10-Year Interest Coverage Range
Min: -1000   Max: 1000
Current: No Debt

-1000
1000
F-Score: 1
Z-Score: -19.62
M-Score: -46.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -3156.26
CYCCP's Operating margin (%) is ranked higher than
54% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. CYCCP: -3156.26 )
CYCCP' s 10-Year Operating margin (%) Range
Min: -115336.4   Max: 19636.4
Current: -3156.26

-115336.4
19636.4
Net-margin (%) -3306.17
CYCCP's Net-margin (%) is ranked higher than
56% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. CYCCP: -3306.17 )
CYCCP' s 10-Year Net-margin (%) Range
Min: -152366.7   Max: -463.3
Current: -3306.17

-152366.7
-463.3
ROE (%) -74.63
CYCCP's ROE (%) is ranked higher than
66% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. CYCCP: -74.63 )
CYCCP' s 10-Year ROE (%) Range
Min: -373.6   Max: -19.6
Current: -74.63

-373.6
-19.6
ROA (%) -57.86
CYCCP's ROA (%) is ranked higher than
67% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. CYCCP: -57.86 )
CYCCP' s 10-Year ROA (%) Range
Min: -169.6   Max: -16.8
Current: -57.86

-169.6
-16.8
Revenue Growth (%) -24.00
CYCCP's Revenue Growth (%) is ranked higher than
97% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. CYCCP: -24.00 )
CYCCP' s 10-Year Revenue Growth (%) Range
Min: -53.3   Max: 27
Current: -24

-53.3
27
EBITDA Growth (%) -36.50
CYCCP's EBITDA Growth (%) is ranked higher than
57% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. CYCCP: -36.50 )
CYCCP' s 10-Year EBITDA Growth (%) Range
Min: -45.1   Max: 8.3
Current: -36.5

-45.1
8.3
» CYCCP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CYCCP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Cyclacel Pharmaceuticals Inc

SymbolPriceYieldDescription
CYCCP8.077.406% Convertible Exchangeable Preferred Stock

Ratios

vs
industry
vs
history
EV-to-EBIT 0.10
CYCCP's EV-to-EBIT is ranked higher than
82% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CYCCP: 0.10 )
CYCCP' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 0.1

Current Ratio 5.65
CYCCP's Current Ratio is ranked higher than
72% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. CYCCP: 5.65 )
CYCCP' s 10-Year Current Ratio Range
Min: 0   Max: 0
Current: 5.65

Quick Ratio 5.12
CYCCP's Quick Ratio is ranked higher than
74% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. CYCCP: 5.12 )
CYCCP' s 10-Year Quick Ratio Range
Min: 0   Max: 0
Current: 5.12

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 7.40
CYCCP's Dividend Yield is ranked lower than
345% of the 166 Companies
in the Global Biotechnology industry.

( Industry Median: 1.11 vs. CYCCP: 7.40 )
CYCCP' s 10-Year Dividend Yield Range
Min: 0   Max: 0
Current: 7.4

Yield on cost (5-Year) 7.40
CYCCP's Yield on cost (5-Year) is ranked lower than
336% of the 170 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. CYCCP: 7.40 )
CYCCP' s 10-Year Yield on cost (5-Year) Range
Min: 0   Max: 0
Current: 7.4

Valuation & Return

vs
industry
vs
history

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:UXI2.Germany
Cyclacel Pharmaceuticals, Inc., was founded in 1996, and is incorporated Delaware. The Company is a development-stage biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. The Company develops and commercializes small-molecule drugs that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, particularly those of high unmet medical need. Cyclacel's clinical development priorities are focused on sapacitabine: Acute myeloid leukemia, Myelodysplastic syndromes, and Non-small cell lung cancer.
» More Articles for CYCCP

Headlines

Articles On GuruFocus.com
Insider Cluster Buying Reported in Several Companies May 30 2013 
View on CYCC Sep 11 2010 
Cyclacel Pharmaceuticals Inc. Reports Operating Results (10-K/A) May 17 2010 
Cyclacel Pharmaceuticals Inc shares climb 166% in two days Jan 10 2010 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 

More From Other Websites
Cyclacel Pharmaceuticals to Present at 9th Annual JMP Securities Healthcare Conference Jun 17 2014
Cyclacel Pharmaceuticals Provides Update on Its Clinical Development Plan of Sapacitabine for... May 31 2014
Cyclacel Pharmaceuticals to Webcast Institutional Investor and Analyst Presentation on Clinical... May 28 2014
Cyclacel Pharmaceuticals Reports First Quarter 2014 Financial Results May 13 2014
Cyclacel Pharmaceuticals to Release 2014 First Quarter Financial Results May 06 2014
New Japanese Patents Issued Covering Sapacitabine Pharmaceutical Formulations and Combination... May 05 2014
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results Mar 25 2014
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2013 Financial Results Mar 13 2014
Cyclacel Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference Feb 03 2014
Cyclacel Reviews 2013 Achievements and Announces Key Business Objectives for 2014 Jan 13 2014
Cyclacel Pharmaceuticals to Present at Biotech Showcase(TM) 2014 Conference Jan 06 2014
2013 ASH 682-06 MDS Poster Dec 09 2013
Cyclacel Reports New Phase 2 Data of Sapacitabine for MDS at ASH Dec 09 2013
Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3... Nov 25 2013
Cyclacel Reports Third Quarter 2013 Financial Results Nov 12 2013
Researchers to Present New Phase 2 Data on Sapacitabine as a Treatment for Patients With MDS at ASH... Nov 07 2013
Cyclacel Pharmaceuticals to Release Third Quarter 2013 Financial Results Nov 06 2013
New US Patents Issued Covering Sapacitabine Use With Hypomethylating Agents and Sapacitabine Dosing... Nov 05 2013
Cyclacel Pharmaceuticals to Present at the 2013 Therapeutic Area Partnerships Conference Oct 31 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide